Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry

References

• Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Listing J, Zink A; The German Study Group of Pediatric Rheumatologists. Health care provision in pediatric rheumatology in Germany–national rheumatologic database. J Rheumatol 2002;29:622–8.
   PubMed Web of Science ®Google Scholar
• Danner S, Sordet C, Terzic J, Donato L, Velten M, Fischbach M, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006;33:1377–81.
   PubMed Web of Science ®Google Scholar
• Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10:3049–60.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al.; The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043–9.
   PubMed Web of Science ®Google Scholar
• Dueckers G, Guellac N, Arbogast M, Dannecker G, Foeldvari I, Frosch M, et al. [Evidence and consensus based treatment guidelines 2010 for juvenile idiopathic arthritis by the German Society of Paediatric Rheumatology], in German. Klin Padiatr 2011;223:386–94.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465–82.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810–20.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Ruperto N, Lovell DJ, Horneff G, Huppertz HI, Quartier P, et al. Uveitis associated to polyarticular juvenile idiopathic arthritis [abstract]. Arthritis Rheumatol 2016;68(suppl 10). (http://acrabstracts.org/abstract/uveitis-associated-to-polyarticular-juvenile-idiopathic-arthritis/).
   Google Scholar
• Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. ADA plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017;376:1637–46.
   PubMed Web of Science ®Google Scholar
• Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Effectiveness and safety of ADA as the first and second biologic agent in juvenile idiopathic arthritis: the German biologics JIA registry. Arthritis Rheumatol 2014;66:2580–9.
   PubMed Web of Science ®Google Scholar
• Anink J, Otten MH, Gorter AL, Prince FH, van Rossum MA, van den Berg JM, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford) 2013;52:1674–9.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA registry. J Rheumatol 2012;39:1867–74.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to ADA: relationship to anti‐ADA antibodies and serum ADA concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921–6.
   PubMed Web of Science ®Google Scholar
• Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638–44.
   PubMed Web of Science ®Google Scholar
• Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D. Safety and effectiveness of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis 2009;68:519–25.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658–66.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929–36.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012;64:2366–74.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Ruperto N, Dressler F, Häfner R, Küster RM, Michels H, et al. The German version of the Childhood Health Assessment Questionaire (CHAQ) and the child health questionaire. Clin Exp Rheumatol 2001;19(Suppl 23):71–4.
   Google Scholar
• ICH. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2) (www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4_2016_1109.pdf). Accessed 27 July 2017.
   Google Scholar
• Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, et al. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER registry. Clin Exp Rheumatol 2016;34:1113–20.
   PubMed Web of Science ®Google Scholar
• Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013;CD004524.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Wallace C, Toth M, Foeldvari I, Bohnsack J, et al. Safety and effectiveness of adalimumabmethotrexate for the treatment of Polyarticular Juvenile Idiopathic Arthritis (PJIA): strive registry [THU0216]. Ann Rheum Dis 2016;75(Suppl 2):266.
   Web of Science ®Google Scholar
• Brunner H, Ruperto N, Nanda K, Toth M, Foeldvari I, Bohnsack JF, et al. Safety of ADA ± methotrexate for the treatment of polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE registry [abstract]. Arthritis Rheumatol 2017;69. (http://acrabstracts.org/abstract/safety-of-ADA-%c2%b1-methotrexate-for-the-treatment-of-polyarticular-juvenile-idiopathic-arthritis-pjia-strive-registry/).
   Web of Science ®Google Scholar